Platelet rich fibrin and simvastatin-loaded pectin-based 3D printed-electrospun bilayer scaffold for skin tissue regeneration
In this study, a bilayer scaffold (BS) with a top layer (TL) comprising 3D printed pectin/polyacrylic acid/platelet rich fibrin hydrogel (Pec/PAA/PRF) and a bottom nanofibrous layer (NL) containing Pec/PAA/simvastatin (SIM) was produced. The biodegradable and biocompatible polymers Pec and PAA were cross-linked to form hydrogels via Ca2+ activation through galacturonate linkage and chelation, respectively. PRF as an autologous growth factor (GF) source and SIM together augmented angiogenesis and neovascularization. Because of 3D printing, the BS possessed a uniform distribution of PRF in TL and an average fiber diameter of...
Source: International Journal of Biological Macromolecules - March 18, 2024 Category: Biochemistry Authors: Mohamadreza Tavakoli Mastafa H Al-Musawi Alma Kalali Afrooz Shekarchizadeh Yeganeh Kaviani Agrin Mansouri Sepideh Nasiri-Harchegani Anousheh Zargar Kharazi Fariborz Sharifianjazi Mamoona Sattar Jaleh Varshosaz Morteza Mehrjoo Aliakbar Najafinezhad Marjan Source Type: research
Cardiovascular/anti ‐inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta‐analysis of randomized trials
Conclusions and RelevanceDespite promising pre-clinical and population-based data, cardiovascular drugs and anti-inflammatory medications have overall not demonstrated benefit in the treatment or preventing recurrence of cancer. These findings may help guide future potential clinical trials involving these medications when applied in oncology. (Source: Cancer Medicine)
Source: Cancer Medicine - March 16, 2024 Category: Cancer & Oncology Authors: David J. Benjamin,
Alyson Haslam,
Vinay Prasad Tags: RESEARCH ARTICLE Source Type: research
Physiologically based pharmacokinetic modeling of imatinib and N ‐desmethyl imatinib for drug–drug interaction predictions
AbstractThe first-generation tyrosine kinase inhibitor imatinib has revolutionized the development of targeted cancer therapy and remains among the frontline treatments, for example, against chronic myeloid leukemia. As a substrate of cytochrome P450 (CYP) 2C8, CYP3A4, and various transporters, imatinib is highly susceptible to drug –drug interactions (DDIs) when co-administered with corresponding perpetrator drugs. Additionally, imatinib and its main metaboliteN-desmethyl imatinib (NDMI) act as inhibitors of CYP2C8, CYP2D6, and CYP3A4 affecting their own metabolism as well as the exposure of co-medications. This work pr...
Source: CPT: Pharmacometrics and Systems Pharmacology - March 14, 2024 Category: Drugs & Pharmacology Authors: Helena Leonie Hanae Loer,
Christina Kovar,
Simeon R üdesheim,
Fatima Zahra Marok,
Laura Maria Fuhr,
Dominik Selzer,
Matthias Schwab,
Thorsten Lehr Tags: ARTICLE Source Type: research
Immediately placed implants using simvastatin and autogenous tooth graft combination in periodontally compromised sites: a randomized controlled clinical trial
ConclusionSMV combined with ATBG boosts the hard tissue parameters around dental implants over ATBG alone. Clinical trial registration was on August 1, 2021 (NCT04992416).Clinical relevanceATBG with SMV in periodontally compromised sites could improve implant osseointegration and promote favorable changes in peri-implant tissues. (Source: Clinical Oral Investigations)
Source: Clinical Oral Investigations - March 12, 2024 Category: Dentistry Source Type: research
Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
CONCLUSION: We utilized a miniaturized tumor-immune model to enable time and cost-effective evaluation of a broad panel of drugs in an immuno-oncology setting in vitro. Using this approach, immunomodulatory effects exerted by TKIs and statins were identified.PMID:38444002 | DOI:10.1186/s40360-024-00746-6 (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - March 5, 2024 Category: Drugs & Pharmacology Authors: Tove Selvin Malin Berglund Lena Lenhammar Magnus Lindskog Malin Jarvius Rolf Larsson Peter Nygren M årten Fryknäs Claes R Andersson Source Type: research
Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
CONCLUSION: We utilized a miniaturized tumor-immune model to enable time and cost-effective evaluation of a broad panel of drugs in an immuno-oncology setting in vitro. Using this approach, immunomodulatory effects exerted by TKIs and statins were identified.PMID:38444002 | PMC:PMC10913607 | DOI:10.1186/s40360-024-00746-6 (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - March 5, 2024 Category: Drugs & Pharmacology Authors: Tove Selvin Malin Berglund Lena Lenhammar Magnus Lindskog Malin Jarvius Rolf Larsson Peter Nygren M årten Fryknäs Claes R Andersson Source Type: research
